This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy volunteers. The study will assess changes in fasting blood glucose, insulin, and C-peptide levels following two days of statin administration under controlled conditions. The research seeks to provide comparative data on the potential diabetogenic effects of these medications.

This study addresses emerging evidence suggesting statin therapy may modestly increase diabetes risk in a dose-dependent manner. The trial will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. Blood glucose will be measured using standardized glucometers, while insulin and C-peptide levels will be determined using ELISA assays. The study aims to clarify whether different statins have varying effects on glucose metabolism during short-term exposure and to establish dose-response relationships.

Inclusion Criteria:

• healthy volunteers
• Non diabetic
• blood glucose level (less than140 mg/dl)

Exclusion Criteria:

• Participants with a history of diabetes mellitus
• With chronic diseases e.g heart disease, kidney disease
• participants taking other medications

The study results will be shared in Journals without the participant identifiers.

The PI will give the assigned medication to each participant according to randomization and allocation. All the personnel involved in the study will be kept blind.